Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Cancer Immunol Res. 2020 Apr 22;8(8):1075–1084. doi: 10.1158/2326-6066.CIR-19-0866

Figure 2. Analysis of survival outcomes in patients with loss of function (LOF) mSWI/SNF and wild-type (WT) across different tumor histologies.

Figure 2.

A. Adjusted hazard ratios (HR) for time to treatment failure in the DFCI cohort (N=676). B. Adjusted HRs for overall survival in the DFCI cohort. C. Adjusted HRs for overall survival in the MSKCC cohort (N=848). Chi-square Wald statistic. CI: confidence interval. Cohort adjustments indicated. Error bars represent SD.